Ace Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Angiotensin-converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase that plays a central role in the renin-angiotensin system[1]. The protein exists in two forms: somatic ACE (found in vascular endothelium) and germinal ACE (found in testis). ACE is a major therapeutic target for cardiovascular disease and has implications in neurodegenerative diseases[2]. Beyond its classical role in blood pressure regulation, ACE has been increasingly recognized for its roles in neuroinflammation, synaptic function, and cognitive processes.
| Attribute | Value |
|---|---|
| Protein Name | Angiotensin-Converting Enzyme |
| Gene | ACE |
| UniProt ID | P12821 |
| PDB Structures | 1O86, 1UZF, 2C6N |
| Molecular Weight | ~170 kDa (somatic) |
| Subcellular Localization | Plasma membrane (type I transmembrane) |
| Protein Family | M2 metalloprotease family |
ACE is a type I transmembrane glycoprotein with:
Each catalytic domain can hydrolyze substrates independently, but the N-terminal domain is the primary site for angiotensin I conversion[3]. The two domains share 60% sequence homology but have distinct substrate specificities.
ACE catalyzes two important reactions:
Key functions:
ACE-generated angiotensin II acts through two receptor subtypes:
ACE exhibits tissue-specific expression:
| Tissue | Expression Level | Form |
|---|---|---|
| Lung endothelium | High | Somatic ACE |
| Vascular endothelium | High | Somatic ACE |
| Brain (neurons, glia) | Moderate | Somatic ACE |
| Testis | Low | Germinal ACE |
| Kidney | Moderate | Somatic ACE |
| Heart | Moderate | Somatic ACE |
In the brain, ACE is expressed in:
ACE uses a zinc-dependent mechanism:
. Zinc1 ion (Zn²⁺) coordinated by three histidine residues
2. Water molecule activated for nucleophilic attack
3. Peptide bond hydrolysis
4. Product release
In the central nervous system, ACE:
| Drug Class | Examples | Mechanism | CNS Penetration |
|---|---|---|---|
| ACE inhibitors | Captopril, Enalapril, Lisinopril | Bind to zinc-binding site, block catalysis | Low |
| Brain-penetrant ACE inhibitors | Perindopril, Trandolapril | Cross BBB, potential neuroprotection | High |
ACE activity is being explored as:
Key findings from animal studies:
[1] Riordan JF. Angiotensin-converting enzyme: from zinc metallopeptidase. Ann N Y Acad Sci. 2001;947:67-76. PMID:11795238
[2] Kehoe PG, et al. Angiotensin-converting enzyme and Alzheimer's disease. Nat Rev Neurol. 2009;5(10):533-538. PMID:19763147
[3] Bernstein KE, et al. A modern understanding of ACE. Am J Physiol. 2005;289(4):F613-621. PMID:16143598
[4] Vardy ER, et al. ACE inhibitors and Alzheimer's disease. J Alzheimers Dis. 2015;45(2):377-387. PMID:25537020
[5] Liu H, et al. ACE I/D polymorphism and Parkinson's disease. Neurol Sci. 2017;38(5):791-796. PMID:28271282
[6] Jiang T, et al. Angiotensin-converting enzyme in neurodegeneration. Prog Neurobiol. 2022;208:102173. PMID:35176482
[7] O'Dwyer G, et al. ACE and Alzheimer's disease. J Mol Neurosci. 2010;40(1-2):211-215. PMID:20082152
The study of Ace Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Riordan JF. Angiotensin-converting enzyme: from zinc metallopeptidase. Ann N Y Acad Sci. 2001;947:67-76. PMID:11795238 ↩︎
Kehoe PG, et al. Angiotensin-converting enzyme and Alzheimer's disease. Nat Rev Neurol. 2009;5(10):533-538. PMID:19763147 ↩︎
Bernstein KE, et al. A modern understanding of ACE. Am J Physiol. 2005;289(4):F613-621. PMID:16143598 ↩︎
Vardy ER, et al. ACE inhibitors and Alzheimer's disease. J Alzheimers Dis. 2015;45(2):377-387. PMID:25537020 ↩︎
Liu H, et al. ACE I/D polymorphism and Parkinson's disease. Neurol Sci. 2017;38(5):791-796. PMID:28271282 ↩︎